CBS 2019
CBSMD教育中心
中 文

动脉粥样硬化性心血管疾病预防

Abstract

Recommended Article

Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar Colchicine Reduces Cardiovascular Events in Chronic Coronary Disease Systemic microvascular dysfunction in microvascular and vasospastic angina Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study Mediterranean Diet and the Association Between Air Pollution and Cardiovascular Disease Mortality Risk Atherosclerosis — An Inflammatory Disease Plasma Ionized Calcium and Risk of Cardiovascular Disease: 106 774 Individuals from the Copenhagen General Population Study Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis

Guideline31 August 2019

JOURNAL:Eur Heart J. Article Link

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

F Mach, C Baigent, ESC Scientific Document Group et al. Keywords: Guidelines; dyslipidaemias; cholesterol; triglycerides; low-density lipoproteins; high-density lipoproteins; apolipoprotein B; lipoprotein(a); lipoprotein remnants; total cardiovascular risk; treatment (lifestyle); treatment (drugs); treatment (adherence); very low-density lipoproteins; familial hypercholesterolaemia

FULL TEXT PDF